States with medical cannabis laws had 24.8% lower opioid overdose mortality — but a later follow-up through 2017 found the association disappeared, suggesting the relationship is more complex than simple substitution.
Policymakers, public health researchers, cannabis advocates, anyone evaluating the opioid-cannabis connection.
24.8% — lower opioid overdose mortality in states with medical cannabis laws
The Backstory
Between 1999 and 2010, prescription opioid overdose deaths in the United States more than quadrupled. By the end of the decade, opioids were killing more Americans than car accidents. The medical establishment that had created the crisis — prescribing opioids aggressively for chronic pain on the basis of pharmaceutical industry assurances that turned out to be catastrophically wrong — was scrambling for solutions.
Into this landscape, Marcus Bachhuber published a finding that made policymakers sit up: states that had legalized medical marijuana were seeing fewer opioid deaths. Not just a little fewer. Nearly 25% fewer.
The implication was enormous and immediately controversial. Could legal access to cannabis — a less dangerous pain treatment — be saving lives by reducing opioid use at the population level?
The Analysis
Bachhuber's team used death certificate data from all 50 states over twelve years (1999-2010), comparing opioid overdose mortality rates in states with and without medical cannabis laws. The analysis controlled for state-level differences using fixed effects models, incorporated opioid-related policies (prescription drug monitoring programs, pain clinic laws, state medical examiner requirements), and adjusted for unemployment rates.
24.8%
lower mean annual opioid overdose mortality rate in states with medical cannabis laws compared to states without — after controlling for state and year fixed effects, opioid policies, and economic conditions (95% CI: -37.5% to -9.5%, p = 0.003).
The association strengthened over time: -19.9% in the first year of implementation, growing to -33.3% by year six. This temporal pattern suggests a cumulative effect — as dispensaries opened, as patients gained access, as substitution patterns took hold, the opioid death reduction deepened.
Bachhuber et al. (2014), JAMA Intern Med 174(10):1668-1673
The trajectory was striking. The longer a state had medical cannabis laws, the larger the reduction in opioid deaths. This dose-response relationship in time — not just "states with laws had fewer deaths" but "the effect grew stronger the longer the laws were in effect" — was the single most persuasive element of the analysis.
What This Study Can and Cannot Tell Us
The Case for a Real Effect
strong- 24.8% reduction is large and statistically robust (p = 0.003)
- Dose-response over time — effect deepens the longer laws are in place
- Biologically plausible: cannabis is a less dangerous alternative for chronic pain
- Consistent with patient-level data showing opioid substitution (Boehnke, Bradford studies)
- Controlled for other opioid policies, economic conditions, and state-level trends
- Published in JAMA Internal Medicine — top-tier peer review
The Case for Caution
strong- Ecological design: compares states, not individuals. Cannot prove any individual patient substituted cannabis for opioids
- States that legalized medical cannabis may differ from other states in unmeasured ways
- A follow-up study (Shover et al., 2019) using data through 2017 found the association reversed — states with laws showed MORE opioid deaths in later years
- The opioid crisis evolved dramatically after 2010 — heroin and fentanyl changed the equation
- Medical cannabis laws were one of many policy changes happening simultaneously
- Correlation between state-level policies and state-level outcomes doesn't establish individual-level mechanisms
Bachhuber et al. (2014); Shover et al. (2019)
The Shover follow-up deserves attention. When researchers extended Bachhuber's analysis through 2017, the protective association disappeared — and in some models reversed. This doesn't necessarily invalidate the original finding. The opioid crisis changed fundamentally between 2010 and 2017: the dominant opioid shifted from prescription pills (which cannabis might plausibly replace for pain) to illicit fentanyl (which is driven by addiction, not pain management). The substitution hypothesis may only apply to the prescription opioid phase of the crisis.
The Policy Impact
Regardless of whether the causal mechanism is proven, Bachhuber's study had outsized influence on cannabis policy. It was cited in:
- State legislative debates on medical cannabis
- Congressional hearings on cannabis rescheduling
- Public health arguments for harm reduction
- Media coverage linking cannabis access to opioid crisis solutions
The finding gave cannabis advocates a powerful talking point: legalization saves lives. It gave policymakers a utilitarian argument beyond individual patient benefit: population-level harm reduction.
Related Research
The Cannabis-Opioid Connection
From population data to individual patients — the evidence for cannabis as an opioid alternative.
Patients prefer cannabis over opioids
Boehnke et al. (2016)
Individual-level data: 64% of medical cannabis patients reduced opioid use. The patient perspective behind the population-level finding.
Cannabis for chronic pain: BMJ meta-analysis
Wang et al. (2021)
The rigorous evidence: cannabis provides small but real pain relief — enough to plausibly reduce opioid demand in some patients.
Cannabinoids for Medical Use
Whiting et al. (2015)
The broader evidence base for medical cannabinoids — moderate evidence for chronic pain
Did medical marijuana laws actually reduce opioid deaths?
The original 2014 analysis found a 24.8% lower opioid overdose mortality rate in states with medical cannabis laws, and the effect deepened over time. However, a 2019 follow-up extending the data through 2017 found the association disappeared and potentially reversed. The relationship appears more complex than a simple substitution effect and may depend on which phase of the opioid crisis is examined (prescription opioids vs. illicit fentanyl). The individual-level evidence for patients substituting cannabis for opioids is more consistent than the state-level ecological data.
Can cannabis replace opioids for pain?
For some patients, partially. Studies consistently show that patients with access to cannabis reduce their opioid use. But the clinical trial evidence shows cannabis provides modest pain relief — it's not a one-to-one replacement for opioids in severe pain. Cannabis is best understood as one tool in a comprehensive pain management strategy that may allow lower opioid doses, not as a complete opioid alternative.
Why did the effect reverse in later years?
The opioid crisis changed fundamentally after 2010. In the early period, deaths were primarily from prescription opioids prescribed for pain — a population where cannabis substitution is plausible. After 2010, deaths increasingly involved illicit heroin and fentanyl, driven by addiction rather than pain management. Cannabis is less likely to substitute for substances driven by addiction physiology than for prescriptions driven by pain treatment choices.
What the researchers found
24.8% lower mean annual opioid overdose mortality in states with medical cannabis laws (95% CI -37.5% to -9.5%, p = 0.003). Effect strengthened over time: -19.9% at year 1 to -33.3% at year 6.
Why it matters
The most influential study linking cannabis policy to opioid crisis outcomes. Shaped legislative debates and policy arguments nationwide. Demonstrated that cannabis access may have population-level harm reduction effects.
How the study worked
Time-series analysis of death certificate data across all 50 US states, 1999-2010. State and year fixed effects. Controlled for prescription drug monitoring programs, pain clinic laws, medical examiner requirements, and unemployment rates.
What this study cannot tell us
Ecological design cannot establish individual-level causation. Follow-up through 2017 (Shover et al.) found association reversed. States with cannabis laws may differ in unmeasured ways. Many concurrent policy changes.
How to read the evidence
Ecological analysis — moderate evidence that cannot establish causation at the individual level. Well-controlled for state-level confounders but subject to the ecological fallacy.
When this study was published
Published 2014, data through 2010. Important context: a 2019 follow-up using data through 2017 found the association reversed.
The bigger picture
Placed cannabis firmly in the opioid policy conversation. The subsequent reversal of the effect in post-2010 data highlights the complexity of ecological analyses and the evolving nature of the opioid crisis.
Questions still open
- Is the substitution effect specific to the prescription opioid era? Does recreational legalization have different effects than medical? What explains the reversal in later data?
Common questions
Read the original research
Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.
JAMA Internal Medicine, 174(10), 1668-1673
Citation
Bachhuber, Marcus A; Saloner, Brendan; Cunningham, Chinazo O; Barry, Colleen L. (2014). Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.. JAMA Internal Medicine, 174(10), 1668-1673. https://doi.org/10.1001/jamainternmed.2014.4005